VistaGen Therapeutics (NASDAQ:VTGN) Stock Crosses Above 50-Day Moving Average – Time to Sell?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.60 and traded as high as $0.61. VistaGen Therapeutics shares last traded at $0.5868, with a volume of 317,574 shares.

Analyst Upgrades and Downgrades

VTGN has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $0.95.

VistaGen Therapeutics Trading Up 4.0%

The company has a market cap of $24.19 million, a P/E ratio of -0.32 and a beta of 0.31. The business’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $1.68.

VistaGen Therapeutics (NASDAQ:VTGN) last released its earnings results on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.14 million. Sell-side analysts anticipate that VistaGen Therapeutics, Inc. will post -1.88 EPS for the current year.

Institutional Investors Weigh In On VistaGen Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VTGN. Bank of America Corp DE grew its holdings in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after buying an additional 19,331 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in VistaGen Therapeutics during the 1st quarter valued at approximately $25,000. Marshall Wace LLP purchased a new stake in VistaGen Therapeutics during the 2nd quarter valued at approximately $69,000. Jane Street Group LLC purchased a new stake in VistaGen Therapeutics during the 2nd quarter valued at approximately $190,000. Finally, AdvisorShares Investments LLC grew its holdings in VistaGen Therapeutics by 1.9% during the 3rd quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock valued at $735,000 after buying an additional 3,884 shares in the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.